{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'The 28 joints evaluated for the SJC and TJC are as follows:', 'Shoulders, elbows, wrists, IP on digit 1, PIP on digits 2 to 5, MCP on digits 1 to 5, and', 'knees', 'Details of the joint assessment process are provided in Section 7.1.2.', '7.1.7', 'Disease Activity Score 28-Joint Count (Erythrocyte Sedimentation Rate)', 'The DAS28 (ESR) will not be calculated by the Investigator during the course of the study,', 'but will be computed in the statistical database for analysis purposes.', 'The DAS28 (ESR) will be calculated using the SJC (28 joints), TJC (28 joints),', 'ESR (mm/hour), and the Patient Global Assessment of Disease Activity (VAS) (in mm)', 'according to the following formula:', 'DAS28 (ESR) = 0.56 X N(TJC) + 0.28 X N(SJC) + 0.70 X lognat (ESR) + 0.014 X Patient', 'Global Assessment of Disease Activity (VAS)', 'The 28 joints evaluated for the SJC and TJC are as follows:', 'Shoulders, elbows, wrists, IP on digit 1, PIP on digits 2 to 5, MCP on digits 1 to 5, and', 'knees', 'Details of the joint assessment process are provided in Section 7.1.2.', '7.1.8', 'Simplified Disease Activity Index', 'The SDAI will not be calculated by the Investigator during the course of the study, but will', 'be computed in the statistical database for analysis purposes.', 'The SDAI will be calculated using the SJC (28 joints), TJC (28 joints), CRP (mg/dL), the', 'Patient Global Assessment of Disease Activity (VAS) (in cm), and the Physician Global', 'Assessment (VAS) (in cm) according to the following formula:', 'SDAI = SJC + TJC + Patient Global Assessment of Disease Activity (VAS) + Physician', 'Global Assessment (VAS) + CRP', '7.1.9', 'Clinical Disease Activity Index', 'The CDAI will not be calculated by the Investigator during the course of the study, but will', 'be computed in the statistical database for analysis purposes.', 'Amendment 2: 06 March 2019', '92', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'The CDAI will be calculated using the SJC (28 joints), TJC (28 joints), the Patient Global', 'Assessment of Disease Activity (VAS) (in cm), and the Physician Global Assessment (VAS)', '(in cm) according to the following formula:', 'CDAI = SJC + TJC + Patient Global Assessment of Disease Activity (VAS) + Physician', 'Global Assessment (VAS)', '7.1.10', 'Health Assessments and Patient-Reported Outcomes', 'The PROs that will be utilized for efficacy assessments are discussed in this section.', '7.1.10.1 Health Assessment Questionnaire - Disability Index', 'The HAQ-DI is a patient-reported questionnaire that provides an assessment of the impact of', 'the disease and its treatment on physical function. The HAQ-DI assesses the degree of', 'difficulty experienced in 8 domains of daily living activities using 20 questions. The', 'domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip, and', 'common daily activities, and each domain (activity) consists of 2 or 3 items. For each', 'question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty,', '1 = with some difficulty, 2 = much difficulty, and 3 = unable to do. Each category is given a', 'score by taking the maximum score of each question (i.e., question in each category with the', 'highest score for that category).', 'If the maximum score is 0 or 1, but a device related to that category is used, or help from', 'another person is provided for the category, then the category score is increased to 2. If the', 'category score is already a 2 (or above), the score in that category remains 2 with or without', 'any aids or device use. If the subject does not provide an answer for any questions within a', 'category, no score will be provided for that category. The HAQ-DI will be calculated by', 'dividing the sum of the category scores by the number of categories with at least 1 question', 'answered. If fewer than 6 categories have responses, no disability score will be calculated.', 'The HAQ-DI will also include patient assessments of pain and health on a scale of 0 to 100.', '7.1.10.2 Short Form-36', 'The SF-36 health survey is a patient-reported survey of health; it is commonly used in health', 'economics as a variable in the quality-adjusted life year (QALY) calculation to determine the', 'cost-effectiveness of a health treatment. The SF-36 consists of 8 scaled scores, which are the', 'weighted sums of the questions in their section. Each scale is directly transformed into a 0 to', '100 scale on the assumption that each question carries equal weight. The lower the score the', 'more disability. The higher the score, the less disability (i.e., a score of zero is equivalent to', 'maximum disability and a score of 100 is equivalent to no disability).', 'Amendment 2: 06 March 2019', '93', 'Confidential']\n\n###\n\n", "completion": "END"}